Avanza Fonder Appoints Northern Trust to Provide Integrated Trading Solutions
Selected as a Provider of Trading Servicesfor Selected Index Funds Managed by Avanza Fonder
Northern Trust (Nasdaq: NTRS) today announced its Integrated Trading Solutions (ITS) outsourced trading desk is supporting Avanza Fonder, a Stockholm-based fund company providing services for private clients.
Founded in 2006, Avanza Fonder is a wholly owned subsidiary of Avanza Bank Holding AB (publ). The fund company manages funds in-house and in collaboration with other managers. Northern Trust will provide outsourced trading primarily for Avanza Fonder’s Global, Emerging Market, European and US equity market index funds.
Gerard Walsh, global head of Client Solutions Banking & Markets, atNorthern Trust,said: “We are delighted to be working with Avanza Fonder, a leading fund manager in the Nordic region, to support them across the trading spectrum through an integrated middle-and back-office solution. Our customised services will help Avanza Fonder navigate ongoing global market challenges, allowing them tofocus on managing the assets entrusted to them, whilst we work with them to effectively manage the trade and post trade lifecycle.”
Petra Sjogeras, head of Nordics at Northern Trust,said: “We are proud to partner with Avanza Fonder as we continue to expand in the Nordic region. We see Nordic managers facing global challenges of rising costs and market volatility. Our Integrated Trading Solution enhances the efficiency of Avanza Fonder’s operating model, mitigates operational challenges and risks and supports the scalability and growth of their business.”
Jesper Bonnivier, CEO of Avanza Fonder, said: “After opting to bring the management of our index funds in-house, we aimed to find a solution that would streamline our trading processes so we could concentrate on what matters most, which is to achieve outstanding results for our clients. By collaborating with Northern Trust and utilizing their ITS platform, we’ve gained access to greater liquidity and scale, enabling us to drive growth and consistently surpass client expectations."
Northern Trust’s outsourced trading capability combines worldwide trading expertise in equities and fixed income, exchange traded derivatives, futures and exchange traded funds (ETFs) across global markets on an agency-only basis. The ITS platform helps asset owners and asset managers to meaningfully lower costs, reduce risk, manage regulatory compliance and enhance transparency and operational efficiency. ITS is offered through Institutional Brokerage, a part of Northern Trust Banking & Markets which also provides foreign exchange, securities lending and transition management services.
About Avanza Fonder
Avanza Fonder is a wholly owned subsidiary of Avanza Bank Holding AB (publ). The fund company was founded in 2006 and the first of its own funds was Avanza Zero – Sweden’s first no-fee index fund – which was launched the same year. Avanza Fonder now has 23 of its own funds, 11 of which it manages itself and 12 that are managed in collaboration with Amundi, TIN Fonder, FCG Fonder, NRP Anaxo Management AS, ARK Investment Management LTD, Coeli Asset Management, HealthInvest Partners AB och Captor Fund Management AB.
About Northern Trust Banking & Markets
Northern Trust Banking & Markets is comprised of a number of Northern Trust entities that provide trading and execution services on behalf of institutional clients, including foreign exchange, institutional brokerage, securities finance and transition management services. Foreign exchange, securities finance and transition management services are provided by The Northern Trust Company (TNTC) globally, and Northern Trust Global Services SE (NTGS SE) in the European Economic Area (EEA). Institutional Brokerage services including ITS are provided by NTGS SE in the EEA, Northern Trust Securities LLP (NTS LLP) in the rest of EMEA, Northern Trust Securities Australia Pty Ltd (NTSA) in APAC and Northern Trust Securities, Inc. (NTSI) in the United States, member FINRA, SIPC and a subsidiary of Northern Trust Corporation.
About Northern Trust
Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of September 30, 2024, Northern Trust had assets under custody/administration of US$17.4 trillion, and assets under management of US$1.6 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on northerntrust.com. Follow us on X (formerly Twitter) @NorthernTrust or Northern Trust Corporation on LinkedIn.
Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at https://www.northerntrust.com/terms-and-conditions
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209919631/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom